Evelo Biosciences


Evelo Biosciences is a clinical stage biotechnology company developing oral biologics that act on cells in the small intestine with systemic therapeutic effects. These cells in the small intestine play a central role in governing the immune, metabolic and neurological systems. The company’s first product candidates are monoclonal microbials, single strains of microbes selected for defined pharmacological properties. They have been observed in preclinical models to have systemic dose-dependent effects, modulating multiple clinically validated pathways. Evelo’s therapies have the potential to be effective, safe and affordable medicines to improve the lives of people with chronic disease and cancer. Evelo currently has three product candidates, EDP1066 and EDP1815 for the treatment of inflammatory diseases and EDP1503 for the treatment of cancer. Evelo is also advancing additional oral biologics through preclinical development in other disease areas.

United States


View Employees

Michele Picard
Director Of Operations at Evelo Biosciences
Joseph Shultz
Vice President Bioprocess and Product Development at Evelo Biosciences
Syed Altaf
Senior Director, Head of Formulation Development at Evelo Biosciences
Diogo Camacho
Senior Scientist, Computational Systems Biology at Evelo Biosciences
Chun Zhang
SVP, Head of Process Development and Manufacturing at Evelo Biosciences
Ellen Stewart
Director, Clinical Data Management at Evelo Biosciences
Debbie Macaro
Senior Clinical Project Manager at Evelo Biosciences
Jonathan Zung Ph.D.
Chief Development Officer at Evelo Biosciences
John Hohneker
Member, Board of Directors at Evelo Biosciences

Find more contacts